ALTERITY THERAPEUTICS TO HOST WEBCAST TO DISCUSS ATH434 EFFICACY DATA IN PRIMATES AND RECENT CLINICAL PROGRESS
Melbourne, Australia and San Francisco – Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a leading biotechnology company focused on developing disease modifying treatments for neurodegenerative diseases, will be holding an investor webcast on Wednesday, December 6, 2023, in Australia and Tuesday, December 5, 2023, in the United States. The webcast, which requires registration, will be led by Alterity’s CEO, Dr. David Stamler, who will delve into the newly released ATH434 efficacy data in primates as well as provide updates on recent clinical progress.
During the webcast, Dr. Stamler will share key insights regarding the ATH434 efficacy data in primates that was unveiled earlier today. This significant development showcases the potential of ATH434 in the treatment of various Parkinsonian disorders. Additionally, he will provide valuable updates on the current Phase 2 clinical trials that are evaluating ATH434’s efficacy in Multiple System Atrophy, a condition characterized by neurodegeneration.
Investors interested in participating can register for the Zoom webcast by visiting the following link: https://us02web.zoom.us/webinar/register/WN_9Lv1OWMtSSSqdJrRsKRiTA#/registration. Registration is mandatory, and dial-in details will be directly provided upon completing the registration process. Investors will have the opportunity to submit questions during the call, following the presentation. Alternatively, questions can be sent in advance to Hannah Howlett at we-aualteritytherapeutics@we-worldwide.com.
Alterity Therapeutics, a clinical-stage biotechnology company, is committed to developing groundbreaking solutions for individuals living with neurodegenerative diseases. The company’s leading candidate, ATH434, possesses immense potential in treating various Parkinsonian disorders, and is currently being evaluated in two Phase 2 clinical trials for Multiple System Atrophy. Alterity’s robust drug discovery platform generates patentable chemical compounds that target the underlying pathology of neurological diseases. With offices in Melbourne, Australia, and San Francisco, California, USA, Alterity Therapeutics is at the forefront of innovative treatments in the field. For further information, please visit www.alteritytherapeutics.com.
The announcement was authorized by Alterity Therapeutics Limited CEO, David Stamler.
In conclusion, Alterity Therapeutics is gearing up to present its highly anticipated investor webcast, wherein CEO Dr. David Stamler will discuss the recently unveiled efficacy data of ATH434 in primates. This event not only sheds light on the promising potential of ATH434 in treating Parkinsonian disorders, but it also provides updates on the ongoing Phase 2 clinical trials in Multiple System Atrophy. Interested investors are encouraged to register for the webcast and take this opportunity to gain valuable insights into Alterity Therapeutics’ groundbreaking developments in neurodegenerative disease treatments.
